GENI.LSE Genincode PLC

Healthcare Biotechnology London Exchange
0.0062 GBX
Close of Nov 3, 2026
0.5610 4.90
Market cap
GBX 4.67M
P/E
-
P/B
2.41x
ROE
-488.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is GENI.LSE undervalued?

Graham number

The Graham number of Genincode PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Genincode PLC fundamental analysis

No fundamental analysis for Genincode PLC yet.

Genincode PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Genincode PLC

GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the pat…

Full company profile